Analyst consensus rating
GT Biopharma Analyst Rating: none
Direct answer
GT Biopharma's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $75.00.
Forecast evidence checked September 12, 2026.
Get free GT Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.61
- Average price target
- $75.00
- High price target
- $75.00
- Low price target
- $75.00
- Low target gap
- +771.1%
- Target upside
- +771.1%
- High target gap
- +771.1%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- September 12, 2026
- Valid through
- September 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for GT Biopharma?
GT Biopharma has a verified none consensus. The same dataset has an average price target of $75.00.
How far are GT Biopharma's low and high targets from the recorded price?
The low target implies +771.1%, while the high target implies +771.1%.
How many analysts are included in GT Biopharma's consensus?
The verified consensus includes 1 analysts.
How is GT Biopharma's target upside or downside calculated?
The average target of $75.00 is divided by the recorded price of $8.61, then one is subtracted to produce +771.1%. This does not guarantee a future return.
When was GT Biopharma's analyst forecast verified?
The data was verified on 2026-09-12. The dataset is valid through 2026-09-19.